Selected breast cancer publications from 2015 authored by DCTB investigators
Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ.
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of
PARP inhibitor sensitivity. Oncotarget. 2015 May 10;6(13):10746-58.
Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E,
Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W,
Celie PH, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde
J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg
S. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Nature. 2015 May 28;521(7553):541-4.
Thomsen KG, Lyng MB, Elias D, Vever H, Knoop AS, Lykkesfeldt AE, Lænkholm A-V,
Ditzel HJ. Gene expression alterations associated with outcome in aromatase inhibitortreated ER+ early-stage breast cancer patients. Breast Cancer Res Treat. In press, 2015.
Wee ZN, SM Yatim, VK Kohlabauer, M Feng, JY Goh, B Yi, P Leng Lee, S Zhang, PP
Wang, WL Tam, Y Cai, HJ Ditzel, DS Hoon, EY Tan, Q Yu. IRAK1 is a therapeutic target
that drives breast cancer metastasis and resistance to paclitaxel. Nature
Communications, 6:8746, 2015.
Kümler I, Stenvang J, Moreira J, Brünner N, Nielsen DL. Drug transporters in breast
cancer: response to anthracyclines and taxanes. Expert Rev Anticancer Ther.
2015;15(9):1075-92.
Ignatiadis M, Azim H, Desmedt C, Veys I, Larsimont D, R Salgado, MB Lyng, G Viale, B
Leyland-Jones, A Giobbie-Hurder, R Kammler, I Laios, P Dell’Orto, HJ Ditzel, M Regan,
M Piccart, S Michiels, C Sotiriou. Genomic grade and centrally-reviewed Ki67 to
determine the risk of distant recurrence in the BIG 1-98 phase III trial. JAMA Oncology, in
press, 2015.
Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, Ozretić L, Künstlinger H,
Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D,
Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R,
Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC. A Synergistic Interaction
between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell. 2015 Jul 2;162(1):14659.
Hubackova S, Kucerova A, Michlits G, Kyjacova L, Reinis M, Korolov O, Bartek J, Hodny
Z. IFNγ induces oxidative stress, DNA damage and tumor cell senescence via
TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2.
Oncogene. 2015 May 18. doi: 10.1038/onc.2015.162. [Epub ahead of print]
Kümler I, Balslev E, Poulsen TS, Nielsen SL, Nygård SB, Rømer MU, Christensen IJ,
Høgdall E, Moreira J, Nielsen DL, Brünner N, Stenvang J. Topoisomerase-1 gene copy
aberrations are frequent in patients with breast cancer. Int J Cancer. 2015 Oct
15;137(8):2000-6. doi: 10.1002/ijc.29556. Epub 2015 Apr 27.
Elias D, HJ Ditzel. The potential of Src inhibitors. Aging. 2015 Oct 2. [Epub ahead of
print]
Lund RR, Leth-Larsen R, Caterino TD, Terp MG, Nissen J, Lænkholm AV, Jensen ON,
Ditzel HJ. NADH-cytochrome b5 reductase 3 promotes colonization and metastasis
formation and is a prognostic marker of disease-free and overall survival in estrogen
receptor-negative breast cancer. Mol Cell Proteomics. 14(11):2988-2999, 2015
Elias D, HJ Ditzel. Fyn is an important molecule in cancer pathogenesis and drug
resistance. Pharmacol Research, 100:250-254, 2015.
Maheswaran E, Pedersen CB, Ditzel HJ, Gjerstorff MF. Lack of ADAM2, CALR3 and
SAGE1 cancer/testis antigen expression in lung and breast cancer. PLoS One.
2015;10(8):e0134967.
Kodahl AR, Pallisgaard N, AM Jylling, Cold S, Knoop AS, Ditzel HJ. Detecting Plasma
Tumor DNA in Early-Stage Breast Cancer - Letter. Clin Cancer Res. 21:3569, 2015.
Kümler I, Parner VK, Tuxen MK, Skjoldbye B, Bergenfeldt M, Nelausen KM, Nielsen DL.
Clinical outcome of percutaneous RF-ablation of non-operable patients with liver
metastasis from breast cancer. Radiol Med. 2015 Jun;120(6):536-41. doi:
10.1007/s11547-014-0489-6. Epub 2015 Jan 9.
Thomsen KG, MG Terp, RR Lund, R Søkilde, D Elias, M Bak, T Litman, HC Beck, MB
Lyng, HJ Ditzel. miR-155, identified as anti-metastatic by global miRNA profiling of a
metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes
significant signaling alterations. Oncotarget 6(30):29224-39, 2015.
Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime
candidates for immunotherapy. Oncotarget 6:15772-15787, 2015.
Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R,
Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, …, Viale G, Rae JM, Regan
MM. YP19A1 polymorphisms and clinical outcomes in postmenopausal women with
hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat.
151:373-384, 2015.
Ehmsen S, Hansen LT, Bak M, Brasch-Andersen C, Ditzel HJ, Leth-Larsen R. S100A14
is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Int J Cancer. 137(9): 2093-103, 2015.
Elle IC, Karlsen KK, Terp MG, Larsen N, Nielsen R, Derbyshire N, Mandrup S, Ditzel HJ,
Wengel J. Selection of LNA-containing DNA aptamers against recombinant human CD73.
Mol Biosyst. 11(5): 1260-1270, 2015
Hansen SN, Westergaard D, Thomsen MB, Vistesen M, Do KN, Fogh L, Belling KC,
Wang J, Yang H, Gupta R, Ditzel HJ, Moreira J, Brünner N, Stenvang J, Schrohl AS.
Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1
expression as a key mediator of resistance accompanied by discrete upregulation of
other specific genes and pathways. Tumour Biol. 6:4327-38, 2015.
Fugger K, Mistrik M, Neelsen KJ, Yao Q, Zellweger R, Kousholt AN, Haahr P, Chu WK,
Bartek J, Lopes M, Hickson ID, Sørensen CS. FBH1 Catalyzes Regression of Stalled
Replication Forks. Cell Rep. 2015 Mar 10. pii: S2211-1247(15)00174-6.
Alsara M, Löffler H, Fechter A, Bartek J, Krämer A. Cep63 recruits cdk1 to the
centrosome-letter. Cancer Res. 2015 Feb 15;75(4):777-8. doi: 10.1158/0008-5472.CAN14-3431.
Kümler I, Balslev E, Stenvang J, Brünner N, Nielsen D. A phase II study of weekly
irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer
and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
BMC Cancer. 2015 Feb 21;15:78.
Elias D, Vever H, Lænkholm A-V, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ.
Gene expression profiling identifies FYN as an important molecule in tamoxifen
resistance and a predictor of early recurrence in patients treated with endocrine therapy.
Oncogene 34:1919-27, 2015